Literature DB >> 15545186

Influence of overall treatment time and radiobiological parameters on biologically effective doses in cervical cancer patients treated with radiation therapy alone.

Anna Gasinska1, Jack F Fowler, Bengt K Lind, Krzysztof Urbanski.   

Abstract

The aim of the study was to examine the influence of overall treatment time (OTT) on the value of calculated biological effective doses (BEDs) for different biological variables. These variables were: tumour proliferation rate, different cell radiosensitivity (alpha=0.2, 0.3, and 0.4 /Gy), and different start time for repopulation (Tk=21, 28, and 35 days). Also the influence of age (</= 50 years >), Hb level (</= 116 g/l>), tumor proliferation rate (bromodeoxyuridine labelling index; BrdUrdLI), and DNA ploidy on survival after shorter (</= 60 days) or longer (>60 days) OTT was investigated. The study included 229 patients with cervix carcinoma treated entirely by standard radiotherapy (RT) (external beam RT plus low-medium dose-rate (LDR/MDR) brachytherapy (BT) at the Center of Oncology in Krakow. The linear quadratic equation was used to calculate BED, which is proportional to log cell kill. BEDs 10 (for tumours) were calculated with consideration of OTT for each patient and tumour proliferation rate (standardized potential doubling time; standardized Tpot) based on BrdUrdLI assessed on biopsy material before RT. Median OTT was 90 days (range 30-210). The mean calculated total BED for point A for tumour and 'early reactions' was equal to 103.0 Gy10. The longest median survival time--52 months--was seen for patients treated with OTT </= 60 days. If OTT exceeded 90 days to more than 120 days, loss in BED10 for relatively radiosensitive tumours (alpha=0.3-0.4/Gy and Tk=28 days) was equal to 0.37-0.26 Gy/day. However, for radioresistant tumours (alpha=0.2/Gy) it was 0.6 Gy/day. For fast proliferating tumours (BrdUrdLI >8.8%) BED loss was 1.4 Gy/day and for slowly proliferating tumours (BrdUrdLI </= 8.8%) it was 0.2 Gy/day. Assuming shorter (21 days) or longer (35 days) periods for Tk and relatively radiosensitive tumours similar BED loss of 0.38 Gy/day was observed. Kaplan-Meier analysis revealed that OTT </= 60 days was a significant prognostic factor for overall survival (OS) (p=0.019), disease-free survival (DFS) (p=0.0173), and local control (LC) (p=0.011). BED10 had significant influence on survival (p=0.047). Cox multivariate analysis revealed that for OTT shorter than 60 days the only favourable significant parameters were: age >50 years (p=0.003) and high Hb level (>116 g/l) (p=0.041). For longer treatments (OTT >60 days) the unfavourable parameters were: age </= 50 years (p=0.037), BrdUrdLI </= 8.8% (p=0.003), tumour aneuploidy (p=0.043), and BED10 </= 103 Gy (p=0.017). The examined tumour biological parameters should be taken into account for RT and provide a basis for adjuvant RT.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15545186     DOI: 10.1080/02841860410018511

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  14 in total

Review 1.  21 years of biologically effective dose.

Authors:  J F Fowler
Journal:  Br J Radiol       Date:  2010-07       Impact factor: 3.039

2.  Pulsed brachytherapy: a modelled consideration of repair parameter uncertainties and their influence on treatment duration extension and daytime-only "block-schemes".

Authors:  T S A Underwood; R G Dale; A M Bidmead; C A Nalder; P R Blake
Journal:  Br J Radiol       Date:  2011-01-25       Impact factor: 3.039

3.  Pattern of care in radiotherapy at a University Hospital in Spain: the RENORT project.

Authors:  J López-Torrecilla; D González Sanchis; D Granero Cabañero; E García Miragall; P Almendros Blanco; A Hernandez Machancoses; L Brualla González; J Pastor Peidro; J C Gordo Partearroyo; J Rosello Ferrando
Journal:  Clin Transl Oncol       Date:  2021-02-14       Impact factor: 3.405

Review 4.  External beam techniques to boost cervical cancer when brachytherapy is not an option-theories and applications.

Authors:  Omar Mahmoud; Sarah Kilic; Atif J Khan; Sushil Beriwal; William Small
Journal:  Ann Transl Med       Date:  2017-05

5.  Biological effective dose evaluation in gynaecological brachytherapy: LDR and HDR treatments, dependence on radiobiological parameters, and treatment optimisation.

Authors:  C Bianchi; F Botta; L Conte; P Vanoli; L Cerizza
Journal:  Radiol Med       Date:  2008-07-10       Impact factor: 3.469

6.  Clinical significance of cumulative biological effective dose and overall treatment time in the treatment of carcinoma cervix.

Authors:  Abhijit Mandal; Anupam Kumar Asthana; Lalit Mohon Aggarwal
Journal:  J Med Phys       Date:  2007-04

7.  Impact of treatment time-related factors on prognoses and radiation proctitis after definitive chemoradiotherapy for cervical cancer.

Authors:  Eng-Yen Huang; Hao Lin; Chong-Jong Wang; Chan-Chao Chanchien; Yu-Che Ou
Journal:  Cancer Med       Date:  2016-07-15       Impact factor: 4.452

8.  Robust prognostic value of a knowledge-based proliferation signature across large patient microarray studies spanning different cancer types.

Authors:  M H W Starmans; B Krishnapuram; H Steck; H Horlings; D S A Nuyten; M J van de Vijver; R Seigneuric; F M Buffa; A L Harris; B G Wouters; P Lambin
Journal:  Br J Cancer       Date:  2008-11-04       Impact factor: 7.640

9.  Biological effective dose evaluation and assessment of rectal and bladder complications for cervical cancer treated with radiotherapy and surgery.

Authors:  Catharina Beskow; Anna-Karin Agren-Cronqvist; Rolf Lewensohn; Iuliana Toma-Dasu
Journal:  J Contemp Brachytherapy       Date:  2012-12-28

10.  Effect of Prolonged Radiotherapy Treatment Time on Survival Outcomes after Intensity-Modulated Radiation Therapy in Nasopharyngeal Carcinoma.

Authors:  Pei-Jing Li; Ting Jin; Dong-Hua Luo; Ting Shen; Dong-Mei Mai; Wei-Han Hu; Hao-Yuan Mo
Journal:  PLoS One       Date:  2015-10-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.